BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn.
$0.82-9.43%
报价 2026-11-13
市值
$2M
EV
$2.1M
PE (TTM)
–
预期 PE
–
52 周区间距高点 -82.9%
$0.82$4.81
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
market cap below $300M floor
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Medical - Diagnostics & Research| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| BGLCBioNexus Gene Lab Corp. | $2M | -9.4% | – | 14.8% | – | – | – | |
| MDXHMDxHealth S.A. | $13.7M | +2.9% | – | 57.6% | – | – | – | |
| DRIODarioHealth Corp. | $12.3M | -23.6% | +17.4% | 56.1% | 3.5x | – | – | |
| NDRAENDRA Life Sciences Inc. | $6.6M | -5.0% | 0.0% | 0% | – | – | – | |
| INBSIntelligent Bio Solutions Inc. | $5.8M | -8.8% | -44.1% | 27.7% | – | – | – | |
| ADVBAdvanced Biomed Inc. Common Stock | $4.2M | -23.6% | – | -3,856.4% | – | – | – | |
| VNRXVolitionRx Limited | $2.8M | +24.7% | +277.8% | 89.6% | – | – | – | |
| MBAICheck-Cap Ltd. Ordinary Share | $2.1M | -1.7% | – | 0% | 0.5x | 0.6x | – | |
| ISPCiSpecimen Inc. | $1.7M | -5.4% | +204.8% | -29.6% | – | – | – | |
| 同行中位数 | – | – | +17.4% | 13.9% | 2.0x | 0.6x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。
研究材料
电话会纪要摘要
暂无纪要摘要。